Drug
IXT-m200
IXT-m200 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 50.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 2 completed trials
Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
200%(4 trials)
Terminated
2(50%)
Phase Distribution
Ph phase_2
2
50%
Ph phase_1
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(2)
Detailed Status
Completed2
Terminated2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
completed250%
terminated250%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_2
Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200
NCT05034874
terminatedphase_2
Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose
NCT04715230
completedphase_1
Safety, Tolerability, and Pharmacokinetics of IXT-m200
NCT05027451
completedphase_1
Study of Antibody for Methamphetamine Outpatient Therapy
NCT03336866
Clinical Trials (4)
Showing 4 of 4 trials
NCT05034874Phase 2
Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200
NCT04715230Phase 2
Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose
NCT05027451Phase 1
Safety, Tolerability, and Pharmacokinetics of IXT-m200
NCT03336866Phase 1
Study of Antibody for Methamphetamine Outpatient Therapy
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4